Literature DB >> 9613987

BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.

F Zaja1, C Di Loreto, V Amoroso, F Salmaso, D Russo, F Silvestri, R Fanin, D Damiani, L Infanti, L Mariuzzi, C A Beltrami, M Baccarani.   

Abstract

Bcl-2 overexpression has been shown to be associated with several malignancies, including B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphomas (NHL), mainly low-grade and follicular in type. It has as yet not been described in hairy cell leukemia (HCL). In 30 patients with CLL and 14 with HCL who were consecutively selected for treatment with purine analogues (Fludarabine in CLL and 2-chloro-deoxy-adenosine in HCL), we evaluated bcl-2 oncoprotein expression in leukemic cells on marrow sections that were taken before treatment and stained immunohistochemically with a monoclonal antibody (Dakopatts 124 clone), by the avidin-biotin-peroxidase method. All samples were found to be bcl-2 positive, with a staining intensity that was moderate to strong in CLL and weak to moderate in HCL. 83% of CLL and 100% of HCL patients were responsive to purine analogues. These findings show that bcl-2 is overexpressed in almost all cases CLL and HCL and that bcl-2 overexpression does not predict a poor response to purine analogues, which are believed to induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613987     DOI: 10.3109/10428199809058365

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.

Authors:  Aksana K Jones; Kevin J Freise; Suresh K Agarwal; Rod A Humerickhouse; Shekman L Wong; Ahmed Hamed Salem
Journal:  AAPS J       Date:  2016-05-27       Impact factor: 4.009

Review 2.  Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.

Authors:  L Loni; M Del Tacca; R Danesi
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

3.  Oblimersen for the treatment of patients with chronic lymphocytic leukemia.

Authors:  Bruce D Cheson
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.